FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096827095> ?p ?o ?g. }

• W3096827095 abstract "Background: Inappropriate use of MRSA-spectrum antibiotics is an important antimicrobial stewardship target. Contributors to inappropriate use include empiric treatment of patients who are determined to not be infected or who are infected but lack MRSA risk factors, and by excessive treatment duration when suspected MRSA infection is disproven. To characterize opportunities for improvement, we conducted a medical use evaluation (MUE) in 27 VA medical centers. The primary objectives were to assess the following proportions: (1) courses of unjustified empiric vancomycin therapy (patients in whom all antibacterials were halted within 2 days or without a principal or secondary discharge infection diagnosis); (2) courses of unjustified continuation of anti-MRSA therapy beyond day 4 (no MRSA risk factors or proven MRSA infection); and (3) excess anti-MRSA days of therapy (DOT), that is, DOT in unjustified empiric courses plus DOT after day 4 in unjustified continued courses. Methods: Clinical pharmacists performed retrospective, structured, manual record reviews of patients started on intravenous vancomycin on day 1 or 2 of hospitalization from June 2017 to May 2018. Exclusion criteria included surgical prophylaxis, recent MRSA infection, β-lactam allergy, renal insufficiency, severe immunosuppression, or infection that warranted anti-MRSA therapy other than vancomycin. Results: Of 2,493 evaluated patients, 1,320 met the inclusion criteria. Among them, 44% of courses were initiated in the emergency department, 37% of patients had ≥1 risk factor for healthcare-associated infections, and 50% of patients had ≥2 SIRS criteria or required vasopressor support. The most common admission diagnoses were skin and soft-tissue infection (SSTI, 40%; 68% nonpurulent) and pneumonia (27%; 46% without healthcare risk factors). Clinical cultures recovered MRSA from 8% of patients. Empiric therapy was not justified in 342 patients (26%; 57% were clinically stable). Continued therapy was unjustified in 46% of the 320 patients who received >4 days of anti-MRSA therapy. Of all days of anti-MRSA therapy, 23% were unjustified; 65% of these were due to unjustified empiric therapy. Site-specific variations in unjustified empiric therapy better correlated with the proportion of unjustified DOT than did unjustified continuation of therapy (Pearson correlation coefficients [PCC], 0.75 and 0.54, respectively) (Fig. 1). Facility-specific proportions of unjustified DOT modestly correlated with anti-MRSA DOT (PCC, 0.45; n = 27) (Fig. 2) but not the anti-MRSA standardized antimicrobial administration ratio (PCC, 0.15; n = 21). Conclusions: In this multicenter MUE, 26% of all days of anti-MRSA therapy lacked justification; this rate correlated with total facility-specific anti-MRSA DOT. Unnecessary empiric therapy, largely in the ED and for nonpurulent SSTIs and pneumonia without risk factors, was the principal contributor to unjustified DOT. Funding: None Disclosures: None" @default.
• W3096827095 created "2020-11-09" @default.
• W3096827095 creator A5004670594 @default.
• W3096827095 creator A5041113330 @default.
• W3096827095 creator A5054976504 @default.
• W3096827095 creator A5068616475 @default.
• W3096827095 creator A5078189187 @default.
• W3096827095 date "2020-10-01" @default.
• W3096827095 modified "2023-09-28" @default.
• W3096827095 title "Appropriateness of Anti-MRSA Therapy in Hospitalized Patients With Suspected Community-Onset Infections" @default.
• W3096827095 doi "https://doi.org/10.1017/ice.2020.635" @default.
• W3096827095 hasPublicationYear "2020" @default.
• W3096827095 type Work @default.
• W3096827095 sameAs 3096827095 @default.
• W3096827095 citedByCount "0" @default.
• W3096827095 crossrefType "journal-article" @default.
• W3096827095 hasAuthorship W3096827095A5004670594 @default.
• W3096827095 hasAuthorship W3096827095A5041113330 @default.
• W3096827095 hasAuthorship W3096827095A5054976504 @default.
• W3096827095 hasAuthorship W3096827095A5068616475 @default.
• W3096827095 hasAuthorship W3096827095A5078189187 @default.
• W3096827095 hasBestOaLocation W30968270951 @default.
• W3096827095 hasConcept C118552586 @default.
• W3096827095 hasConcept C126322002 @default.
• W3096827095 hasConcept C142724271 @default.
• W3096827095 hasConcept C167135981 @default.
• W3096827095 hasConcept C177713679 @default.
• W3096827095 hasConcept C178790620 @default.
• W3096827095 hasConcept C185592680 @default.
• W3096827095 hasConcept C187212893 @default.
• W3096827095 hasConcept C194828623 @default.
• W3096827095 hasConcept C204787440 @default.
• W3096827095 hasConcept C2776040555 @default.
• W3096827095 hasConcept C2778980435 @default.
• W3096827095 hasConcept C2779181126 @default.
• W3096827095 hasConcept C2779489039 @default.
• W3096827095 hasConcept C2780252810 @default.
• W3096827095 hasConcept C2780724011 @default.
• W3096827095 hasConcept C4937899 @default.
• W3096827095 hasConcept C501593827 @default.
• W3096827095 hasConcept C523546767 @default.
• W3096827095 hasConcept C54355233 @default.
• W3096827095 hasConcept C71924100 @default.
• W3096827095 hasConcept C86803240 @default.
• W3096827095 hasConcept C89423630 @default.
• W3096827095 hasConcept C94665300 @default.
• W3096827095 hasConceptScore W3096827095C118552586 @default.
• W3096827095 hasConceptScore W3096827095C126322002 @default.
• W3096827095 hasConceptScore W3096827095C142724271 @default.
• W3096827095 hasConceptScore W3096827095C167135981 @default.
• W3096827095 hasConceptScore W3096827095C177713679 @default.
• W3096827095 hasConceptScore W3096827095C178790620 @default.
• W3096827095 hasConceptScore W3096827095C185592680 @default.
• W3096827095 hasConceptScore W3096827095C187212893 @default.
• W3096827095 hasConceptScore W3096827095C194828623 @default.
• W3096827095 hasConceptScore W3096827095C204787440 @default.
• W3096827095 hasConceptScore W3096827095C2776040555 @default.
• W3096827095 hasConceptScore W3096827095C2778980435 @default.
• W3096827095 hasConceptScore W3096827095C2779181126 @default.
• W3096827095 hasConceptScore W3096827095C2779489039 @default.
• W3096827095 hasConceptScore W3096827095C2780252810 @default.
• W3096827095 hasConceptScore W3096827095C2780724011 @default.
• W3096827095 hasConceptScore W3096827095C4937899 @default.
• W3096827095 hasConceptScore W3096827095C501593827 @default.
• W3096827095 hasConceptScore W3096827095C523546767 @default.
• W3096827095 hasConceptScore W3096827095C54355233 @default.
• W3096827095 hasConceptScore W3096827095C71924100 @default.
• W3096827095 hasConceptScore W3096827095C86803240 @default.
• W3096827095 hasConceptScore W3096827095C89423630 @default.
• W3096827095 hasConceptScore W3096827095C94665300 @default.
• W3096827095 hasLocation W30968270951 @default.
• W3096827095 hasOpenAccess W3096827095 @default.
• W3096827095 hasPrimaryLocation W30968270951 @default.
• W3096827095 hasRelatedWork W1978033345 @default.
• W3096827095 hasRelatedWork W1998378687 @default.
• W3096827095 hasRelatedWork W2026095104 @default.
• W3096827095 hasRelatedWork W2787439413 @default.
• W3096827095 hasRelatedWork W3025950085 @default.
• W3096827095 hasRelatedWork W3092029925 @default.
• W3096827095 hasRelatedWork W3133536779 @default.
• W3096827095 hasRelatedWork W3200197546 @default.
• W3096827095 hasRelatedWork W4280637011 @default.
• W3096827095 hasRelatedWork W4286252226 @default.
• W3096827095 isParatext "false" @default.
• W3096827095 isRetracted "false" @default.
• W3096827095 magId "3096827095" @default.
• W3096827095 workType "article" @default.